Daniel S. Graciaa

Jan 16, 2025 | nature.com | Bo Zhang |Shiyu Chen |Nadine Rouphael |Angela R. Branche |David J. Diemert |Daniel S. Graciaa | +15 more

AbstractNeutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic’s evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate’s contemporary performance.

Aug 28, 2023 | nature.com | Angela R. Branche |David J. Diemert |Susan J Little |Evan Anderson |Angelica C. Kottkamp |Anne F. Luetkemeyer | +19 more

AbstractVaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens.

Jul 13, 2023 | jamanetwork.com | Deborah Theodore |Angela R. Branche |Lily Zhang |Daniel S. Graciaa

Key PointsQuestion  What clinical and demographic factors are associated with rates of COVID-19, severe COVID-19, and SARS-CoV-2 infection? Findings  In this secondary analysis of 57 692 participants randomized to the placebo groups of 4 COVID-19 vaccine phase 3 efficacy trials, exposure risks, demographics (age and race), and evidence of previous infection had the strongest associations with study outcomes.